We are live on ! Find out more
LUMO

Lumos Pharma, Inc. Common Stock

Delisted

LUMO was delisted on the 11th of December, 2024.

94 hedge funds and large institutions have $394M invested in Lumos Pharma, Inc. Common Stock in 2014 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

136% more call options, than puts

Call options by funds: $32.5M | Put options by funds: $13.8M

122% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 9

77% more capital invested

Capital invested by funds: $223M → $394M (+$171M)

44% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 25

13% more funds holding

Funds holding: 8394 (+11)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
94
Holders Change
+11
Holders Change %
+13.25%
% of All Funds
2.72%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
20
Increased
36
Reduced
25
Closed
9
Calls
$32.5M
Puts
$13.8M
Net Calls
+$18.8M
Net Calls Change
-$22.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$104M +$78.6M +256,959 +172%
First Eagle Investment Management
2
First Eagle Investment Management
New York
$33M +$8.72M +28,516 +28%
PC
3
PointState Capital
New York
$29.7M +$7.47M +24,444 +27%
BFA
4
BlackRock Fund Advisors
California
$28.4M +$8.27M +27,036 +32%
Franklin Resources
5
Franklin Resources
California
$25M +$3.62M +11,855 +14%
State Street
6
State Street
Massachusetts
$24.2M +$19.5M +63,884 +209%
Vanguard Group
7
Vanguard Group
Pennsylvania
$14.8M +$2.04M +6,683 +13%
TAM
8
Tiverton Asset Management
Delaware
$11.4M -$3.4M -11,112 -20%
Invesco
9
Invesco
Georgia
$8.55M +$426K +1,393 +4%
WSA
10
Wall Street Associates
California
$8.01M -$2.68M -8,767 -22%
Axa
11
Axa
France
$7.54M +$6.21M +20,302 +221%
UBS AM
12
UBS AM
Illinois
$7.29M +$961K +3,144 +12%
Stifel Financial
13
Stifel Financial
Missouri
$6.49M +$7.76M +25,390 New
SBH
14
Segall Bryant & Hamill
Illinois
$6.42M +$811K +2,654 +12%
Northern Trust
15
Northern Trust
Illinois
$6.33M -$661K -2,162 -8%
BIT
16
BlackRock Institutional Trust
California
$6.2M +$565K +1,848 +8%
EAM
17
Eventide Asset Management
Massachusetts
$6.13M +$1.98M +6,489 +37%
Barclays
18
Barclays
United Kingdom
$3.72M -$3.56M -11,641 -44%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$2.99M +$710K +2,324 +25%
GC
20
Guggenheim Capital
Illinois
$2.96M +$3.54M +11,595 New
CNB
21
City National Bank
California
$2.56M +$942K +3,082 +44%
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$2.34M -$3.67M -12,002 -57%
CS
23
Credit Suisse
Switzerland
$2.3M +$2.3M +7,523 +503%
Geode Capital Management
24
Geode Capital Management
Massachusetts
$2.29M +$183K +597 +7%
KCM
25
Knoll Capital Management
Florida
$2.2M

LUMO Hedge Fund Activity: Q1 2014 in Review

94 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q1 2014, worth a combined $394M — up 77% from $223M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new LUMO positions and 9 closed out — a net gain of 11 holders — while 36 added to existing stakes and 25 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $78.6M. The largest seller was Millennium Management, exiting entirely with an estimated $12.1M sold.

  • 94 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q1 2014, up from 83 in Q4 2013.
  • Funds reported $394M of Lumos Pharma, Inc. Common Stock stock for Q1 2014, up 77% quarter-over-quarter.
  • 20 funds opened new Lumos Pharma, Inc. Common Stock positions in Q1 2014 and 9 closed out, a net change of +11 holders.
  • The largest Lumos Pharma, Inc. Common Stock buyer in Q1 2014 was Fidelity Investments, an estimated $78.6M added.
  • The largest Lumos Pharma, Inc. Common Stock seller in Q1 2014 was Millennium Management, an estimated $12.1M sold.

Based on aggregated 13F filings for Q1 2014.